Advertisement
Screener

EMBECTA CORP. (EMBC) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

EMBECTA CORP. Increase (Decrease) in Accounts Payable and Accrued Liabilities

EMBECTA CORP. (EMBC) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.10 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-07

  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $16.10M, a 387.88% increase year-over-year.
  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $8.80M.
  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$23.80M.
  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$11.70M, a 145.88% decline year-over-year.
  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$68.90M, a 214.83% decline from fiscal 2024.
  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $60.00M, a 659.49% increase from fiscal 2023.
  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $7.90M, a 89.73% decline from fiscal 2022.
  • EMBECTA CORP. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $76.90M, a 91.29% increase from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed
2026-06-30$16.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07
$24.90M
derived: sum of 2 quarters · filed 2026-08-07
$1.10M
10-Q · filed 2026-08-07
-$10.60M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31$8.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05
-$15.00M
10-Q · filed 2026-05-05
-$26.70M
derived: sum of 3 quarters · filed 2026-05-05
-$23.40M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31-$23.80M
10-Q · filed 2026-02-05
-$35.50M
derived: sum of 2 quarters · filed 2026-02-05
-$32.20M
derived: sum of 3 quarters · filed 2026-08-07
-$51.90M
derived: sum of 4 quarters · filed 2026-08-07
2025-09-30-$11.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
-$8.40M
derived: sum of 2 quarters · filed 2026-08-07
-$28.10M
derived: sum of 3 quarters · filed 2026-08-07
-$68.90M
10-K · filed 2025-11-25
2025-06-30$3.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07
-$16.40M
derived: sum of 2 quarters · filed 2026-08-07
-$57.20M
10-Q · filed 2026-08-07
-$31.70M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31-$19.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05
-$60.50M
10-Q · filed 2026-05-05
-$35.00M
derived: sum of 3 quarters · filed 2026-05-05
-$900.00K
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$40.80M
10-Q · filed 2026-02-05
-$15.30M
derived: sum of 2 quarters · filed 2026-02-05
$18.80M
derived: sum of 3 quarters · filed 2026-02-05
$34.90M
derived: sum of 4 quarters · filed 2026-02-05
2024-09-30$25.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
$59.60M
derived: sum of 2 quarters · filed 2025-11-25
$75.70M
derived: sum of 3 quarters · filed 2025-11-25
$60.00M
10-K · filed 2025-11-25
2024-06-30$34.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-08
$50.20M
derived: sum of 2 quarters · filed 2025-08-08
$34.50M
10-Q · filed 2025-08-08
-$10.90M
derived: sum of 4 quarters · filed 2025-11-25
2024-03-31$16.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-09
$400.00K
10-Q · filed 2025-05-09
-$45.00M
derived: sum of 3 quarters · filed 2025-11-25
-$11.40M
derived: sum of 4 quarters · filed 2025-11-25
2023-12-31-$15.70M
10-Q · filed 2025-02-06
-$61.10M
derived: sum of 2 quarters · filed 2025-11-25
-$27.50M
derived: sum of 3 quarters · filed 2025-11-25
-$27.20M
derived: sum of 4 quarters · filed 2025-11-25
2023-09-30-$45.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
-$11.80M
derived: sum of 2 quarters · filed 2025-11-25
-$11.50M
derived: sum of 3 quarters · filed 2025-11-25
$7.90M
10-K · filed 2025-11-25
2023-06-30$33.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09
$33.90M
derived: sum of 2 quarters · filed 2024-08-09
$53.30M
10-Q · filed 2024-08-09
$57.10M
derived: sum of 4 quarters · filed 2024-12-11
2023-03-31$300.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09
$19.70M
10-Q · filed 2024-05-09
$19.50M
10-Q · filed 2023-05-12
$23.50M
derived: sum of 3 quarters · filed 2024-12-11
$111.90M
derived: sum of 4 quarters · filed 2024-12-11
2022-12-31$19.40M
10-Q · filed 2024-02-09
$23.20M
derived: sum of 2 quarters · filed 2024-12-11
$111.60M
derived: sum of 3 quarters · filed 2024-12-11
$98.80M
derived: sum of 4 quarters · filed 2024-12-11
2022-09-30$3.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11
$92.20M
derived: sum of 2 quarters · filed 2024-12-11
$79.40M
derived: sum of 3 quarters · filed 2024-12-11
$76.90M
10-K · filed 2024-12-11
$73.30M
10-K · filed 2022-12-22
2022-06-30$88.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08
$75.60M
derived: sum of 2 quarters · filed 2023-08-08
$73.10M
10-Q · filed 2023-08-08
2022-03-31-$12.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12
-$15.30M
10-Q · filed 2023-05-12
2021-12-31-$2.50M
10-Q · filed 2023-02-14
2021-09-30$40.20M
10-K · filed 2023-11-29
$30.80M
10-K · filed 2022-12-22
2020-09-30-$3.80M
10-K · filed 2022-12-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
Mobia Medical, Inc. (MOBI)United States$0.293B
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
SHOULDER INNOVATIONS, INC. (SI)United States$0.355B
Orchestra BioMed Holdings, Inc. (OBIO)United States$0.356B-4.39
Cytosorbents Corp (CTSO)United States$0.274B-1.29
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
Orthofix Medical Inc. (OFIX)$0.373B
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52